Acquisition of regulatory function by human CD8(+) T cells treated with anti-CD3 antibody requires TNF |
| |
Authors: | Ablamunits Vitaly Bisikirska Brygida Herold Kevan C |
| |
Affiliation: | Departments of Immunobiology and Internal Medicine, Yale University School of Medicine, New Haven, CT 06520, USA. |
| |
Abstract: | Anti-CD3 mAb can modulate graft rejection and attenuate autoimmune diseases but their mechanism(s) of action remain unclear. CD8(+) T cells with regulatory function are induced in vitro by Teplizumab, a humanized anti-CD3 antibody and inhibit responses of autologous and allogeneic T cells. They inhibit CD4(+) T-cell proliferation by mechanisms involving TNF and CCL4, and by blocking target cell entry into G2/M phase of cell cycle but neither kill them, nor compete for IL-2. CD8(+) Treg can be isolated from peripheral blood following treatment of patients with Type 1 diabetes with Teplizumab, but not from untreated patients. The induction of CD8(+) Treg by anti-CD3 mAb requires TNF and signaling through the NF-κB cascade. The CD8(+) Treg express CD25, glucocorticoid-induced TNF receptor family, CTLA-4, Foxp3, and TNFR2, and the combined expression of TNFR2 and CD25 identifies a potent subpopulation of CD8(+) Treg. These studies have identified a novel mechanism of immune regulation by anti-CD3 mAb and markers that may be used to track inducible CD8(+) Treg in settings such as chronic inflammation or immune therapy. |
| |
Keywords: | Anti‐CD3 mAb CD8+ Treg TNF |
本文献已被 PubMed 等数据库收录! |
|